Treatment of scleroderma with collagenase nanocapsules
Scleroderma, or systemic sclerosis, is a chronic connective tissue autoimmune rheumatic disease. Hardening of the skin is the most visible manifestation of the disease, associated with an abnormal accumulation of collagen. Treatment involves the use of proteolytic enzymes such as collagenase, able to digest collagen fibres. However, the labile nature of collagenase compromises its activity in the human body. The goal of the EU-funded DECOMPACT project is to develop and commercialise an improved treatment for scleroderma which involves polymeric collagenase nanocapsules that release protected encapsulated enzymes after UVA irradiation. Novel nanodevices will combine the ability of the proteolytic enzyme to degrade collagen with the immunosuppressive and anti-inflammatory effects of UVA.
Fields of science
Call for proposal
See other projects for this call